When Clinical Response and Concentration Disagree

Why Concentration and Efficacy Can Seem to Disagree

A concentration result is evidence about drug exposure, not a direct measurement of clinical benefit. A patient may have an apparently adequate concentration and inadequate response, or a low measured concentration despite good control. Neither pattern, by itself, proves that the drug is ineffective or that the concentration caused the response. The first task is to establish whether the concentration and the clinical observation can reasonably be compared.

Interpretation depends on what the target concentration represents, when the sample was collected relative to dosing, whether doses were taken as prescribed, and whether the observed outcome could have another explanation. A target is generally a guide based on a specified population, outcome, and sampling context; it is not a guarantee that every patient within its bounds will respond. Conversely, a value outside the target does not establish that the patient lacks benefit.

Establish What Is Being Compared

Before interpreting a mismatch, specify the clinical question. Is the concern inadequate improvement, loss of a previously achieved response, or continued control despite a concentration below a reference target? Clarify which efficacy outcome is being assessed, how it was measured, and over what period. A symptom reported at one visit may not represent the same time window as the concentration in a blood sample.

Next, establish what the target is intended to describe. A target may apply to a particular indication, dosing regimen, sampling time, or population. A trough target cannot be applied directly to a sample taken during absorption or near a peak. A target developed for one indication or outcome may not be informative for another. If the target's intended context does not match the patient's regimen, indication, or sample, the comparison is weak even when the laboratory result is precise.

The earlier material on interpreting concentrations relative to a target distinguishes a reference target from a guaranteed individual response. Here, the important extension is to ask whether the clinical outcome and the target have the same scope. Confirm the drug and analyte being interpreted, the units, the intended sampling phase, and the clinical outcome to which the target relates. Prior assessment of sample metadata and analytical uncertainty matters: an incorrectly timed, contaminated, or uncertain result cannot support a strong exposure–response conclusion.

Why Timing Changes the Meaning of a Result

Concentration varies within a dosing interval. A value collected soon after a dose and a value collected just before the next dose can differ substantially, even when both are measured accurately. The sample time therefore has to be interpreted alongside dose time, route, formulation, and the intended sampling phase. The earlier material on sampling oral drugs during absorption and interpreting concentrations before steady state is relevant when absorption or accumulation may still be changing the profile.

A short derivation illustrates why timing matters. Under a simplified one-compartment model, after absorption is complete and during elimination, concentration declines exponentially. If \(C(t_1)\) is the concentration at time \(t_1\), then at a later time \(t_2\):

Here \(k\) is the elimination rate constant, assumed constant over this interval. Thus, a concentration measured at one time cannot be treated as the concentration at another time without accounting for the elapsed time and the relevant pharmacokinetics. For oral dosing during absorption, this elimination-only expression does not apply as written: absorption may still be increasing concentration. This is why a sample taken at an undocumented or inappropriate time cannot be rescued by simply comparing its number with a trough target.

Clinical response may also reflect exposure over a longer period than the sample represents. Some effects track concentration relatively quickly; others develop or resolve with delay. If the effect lags behind exposure, the current clinical status may reflect earlier dosing and exposure rather than the concentration in today's sample. A single concentration and a single response assessment may therefore refer to different time windows.

Check Adherence Across the Relevant Period

A concentration is influenced by the doses actually taken, not just by the prescribed regimen. Ask about recent missed, delayed, or extra doses, and relate the history to the sample time and the period over which efficacy is being judged. A dose taken shortly before a clinic visit can produce a measurable concentration even if several earlier doses were missed. Conversely, a missed dose near sampling can make a concentration low despite generally consistent use.

Adherence history is not merely a binary label. Record which doses were taken and when, as far as reliable information allows. Consider whether the history covers the time period relevant to both the sample and the expected clinical response. A brief history of missed doses does not quantify exposure precisely, and a reported count should not be converted into a concentration without an appropriate pharmacokinetic model and adequate dosing-time information.

Consider Other Explanations for the Response

When target relevance, sample timing, and adherence have been considered, ask whether the observed response has another explanation. Inadequate efficacy may reflect a diagnosis or disease process not adequately addressed by the drug, a change in disease severity, a coexisting condition, an interacting treatment, or an outcome assessment that is variable or incomplete. The concentration may be consistent with expected exposure while the clinical problem persists for reasons that concentration monitoring cannot resolve.

Likewise, apparent good efficacy at a concentration below a reference target may reflect individual sensitivity, an outcome that has improved for another reason, or a concentration that does not represent the exposure over the relevant period. It is not evidence that the target is universally unnecessary. The interpretation should remain specific to the patient, the indication, the measured outcome, and the limitations of the available observations.

A Structured Diagnostic Sequence

The following sequence keeps the interpretation focused on the efficacy discrepancy rather than turning a single result into a dosing conclusion. Each step narrows what the available evidence can support.

Assumptions, Diagnostics, and Limits

This assessment assumes that the clinical outcome has been measured with reasonable validity, that the concentration result corresponds to the stated analyte and units, and that the available dose and sampling times are sufficiently reliable to place the result in context. It also assumes that the target's intended use is known. If one of these conditions fails, the apparent mismatch may be a data or interpretation problem rather than a clinically meaningful exposure–response finding.

Useful warning signs include an undocumented sample time, use of a trough target for a post-dose sample, a recent dose after several missed doses, a changing regimen, a result obtained before the relevant steady state, or an outcome assessed over a different period from the exposure. A disagreement that remains after these checks is more credible as a possible individual exposure–response difference, but it still does not identify its mechanism.

This approach differs from treating the target as a strict pass/fail boundary. A threshold comparison is quick, but it can hide differences in sampling phase, clinical context, and individual response. A full exposure–response analysis can be more informative when suitable longitudinal exposure and outcome data are available, but such data and a validated model are not always available in routine monitoring. Clinical review integrates the evidence and competing explanations; it does not turn an uncertain concentration into a causal conclusion.

The main limitation is that a concentration is only one piece of evidence. A single value does not necessarily represent exposure across the dosing interval, and even well-characterized exposure does not guarantee a particular response. The analysis should therefore identify what is known, what remains uncertain, and which alternative explanations require clinical assessment. Avoid using an apparent efficacy mismatch to infer toxicity; toxicity and concentration disagreement require a separate assessment.

Common Mistakes

• “The concentration is in range, so the drug must be working.” A target describes a reference context, not a guaranteed individual outcome. Confirm the clinical response and consider alternative explanations.
• “The value is above the trough target, so the patient has more than enough exposure.” If the sample was not collected at the target's specified phase, this comparison is invalid. Establish timing before interpreting the number.
• “The patient took a dose today, so adherence is adequate.” A recent dose cannot establish consistent dosing over the period relevant to exposure or response. Review the dose history across that period.
• “Symptoms persist despite an in-range concentration, so the dose should be increased.” The concentration does not show that greater exposure will improve the outcome. First assess whether the target applies and whether other causes explain the symptoms.
• “A low concentration explains the poor response.” It may be consistent with insufficient exposure, but timing, dose history, target relevance, and the clinical context must support that interpretation.